Integration of a double-stranded DNA copy of the viral RNA into the genome of the infected cell is an essential step in the life cycle of all retroviruses. Although much is still unknown about the process of integration, the development of cell-free integration assays has greatly contributed to the understanding of this process. Cytoplasmic extracts from NIH 3T3 cells infected with a mouse retrovirus, Moloney murine leukemia virus (MoMLV), were shown to contain MoMLV DNA that could be integrated into an exogenous target DNA (1) . By using this in vitro integration system, the structure of the integration intermediate was elucidated (6) .
The basic features of retroviral integration are the following. After reverse transcription and second-strand DNA synthesis, a linear, double-stranded DNA molecule with blunt ends is formed. This DNA copy of the viral genome is flanked by direct repeat sequences called long terminal repeats (LTRs) . At the outer edges of the two LTRs, short, imperfect inverted repeats are present (for a review, see reference 19) . These sequences are sufficient for correct integration (3, 4) . The terminal nucleotides at each 3' end of the blunt-ended DNA are then cleaved off, resulting in the putative immediate precursor for integration (6, 13) . This cleavage reaction is probably executed by the viral integrase protein, which is the only viral protein known to be required for integration (2, 9, 13) . The integrase is encoded by the 3' part of the viral pol gene. A random sequence in the target DNA is cut in a staggered pattern, giving rise to a 5' overhang. The length of this staggered cut is virus specific (20) . The 5' ends of the target DNA are then joined to the viral 3' OH ends. The last step in proviral integration is repair of the gaps present in the intermediate. It is possibly in this step that the terminal nucleotides at each proviral 5' end are lost. The resulting provirus is now flanked by a short direct duplication of the target DNA and terminates with Recently, an assay was described in which cytoplasmic extracts from MoMLV-infected NIH 3T3 cells (or disrupted MoMLV particles) were capable of integrating exogenously added mini-MoMLV DNA into target DNA (5). This assay makes it possible to investigate whether the MoMLV integration machinery is also able to integrate other miniretroviral DNAs, such as mini-human immunodeficiency virus (HIV) DNA. Although the general features of HIV and MoMLV integration are probably similar, there are some clear differences in the actual integration reactions. First, the integrase proteins of HIV and MoMLV are not very similar; there is less than 20% similarity on the amino acid level (7, 8, 17, 21) . Second, the imperfect inverted repeats at the outer edges of the LTRs, the only sequences necessary in cis for correct integration, differ significantly between the two retroviruses. The terminal 18 base pairs (bp) of MoMLV are aligned with the corresponding sequences from HIV-1 and HIV-2. Only 7 of 18 bp at the HIV-1 U3 end match the MoMLV sequence; at the HIV-2 U3 end, the match is 6 of 18 ( Fig. 1B) . At the U5 terminus, the match is 6 (21) through U5 and U3 to the Sacl site at position 9129 in the repeat region. Digestion of pRP131 with NdeI generates a linear mini-HIV-1 with LTR terminal sequences at the ends, which correspond to the U3 and U5 ends of HIV-1, except for the presence of the nucleotides AT at the 5' ends, that are different in wild-type HIV-1 DNAs. Plasmid pRP137 is identical to pRP131 except for the presence of a PvuII site instead of a NdeI site at the boundary between the U3 and U5 LTR terminal sequences. This PvuII site was introduced into the plasmid by site-directed mutagenesis. In addition, pRP137 has a ScaI-PvuII fragment deleted from the U3 sequence. This fragment is located at position 8955 to 9075 in the HIV-1 sequence. Cleavage of plasmid pRP137 by PvuII generates a linear mini-HIV-1 with flush-ended termini. The mini-HIV-2 substrate (pRP255) was constructed by ligation of the oligonucleotide 5'-AATTCTGTAAAACATCCCTTCCATATGCTAGG-GATTTTCCTGCCTGCA-3' and its complement (flanked by EcoRI and PstI cohesive ends) in the vector PiAN7. Digestion of pRP255 with NdeI generates a linear mini-HIV-2 with ends that are identical to the termini of the LTRs of HIV-2 except for the presence of the dinucleotide AT at the 5' ends, which is different in wild-type HIV-2 DNA (7). The control plasmid pRP268 was constructed by cloning the 0.25-kilobase-pair EcoRI-BglIll fragment from pSVsupF (obtained from H. Klein, The Netherlands Cancer Institute, Amsterdam), containing the amber suppressor tRNA gene supF, into the EcoRI and BamHI site of pUC18 (11) . The plasmid was used in integration reactions after linearization by NdeI. The ends of the linearized plasmid do not have obvious similarity to either HIV or MoMLV LTR termini. The sequences that are in bold print should be lost during correct mini-proviral integration into the target DNA. For the MoMLV substrate, the 5 5' ends of the mini-MoMLV substrate (Fig. 1) . Such a substitution, or addition of less than 5 bp to the termini, does not seem to affect correct integration in vivo (13) . The mini-MoMLV DNA resembles the form of MoMLV DNA that is supposed to be the immediate precursor for integration, because it lacks two nucleotides at both 3' ends that are present in the expected full-length product of reverse transcription and second-strand sythesis (6; Fig. 1) .
As a target for integration, bacteriophage lambda Aam Bam Sam DNA was included in the reaction mixture. After incubation, the DNA was recovered from the reaction mixture, and the lambda DNA was packaged in vitro. The resulting phage were then plated on E. coli CA274 [sup' lacZ(Am)]. Phage without insert are not able to grow on the sup' host, since these phage contain amber mutations in three genes that are essential for lytic growth in E. coli.
Upon integration of mini-retroviral DNAs in the phages, however, the supF gene, which is present in the miniretroviral DNAs, is introduced into the phages. As a result, these phages will form plaques on a sup' host, because the amber mutations in the lambda DNAs can be suppressed. An extra control for the presence of the supF gene in these phages is that the plaques are blue in the presence of isopropyl-,-D-thiogalactopyranoside and 5-bromo-4-chloro-3-indolyl-p-D-galactopyranoside, since the host strain contains a lacZ(Am) gene. The results of in vitro experiments with mini-MoMLV DNA (pRP250) as a substrate are shown in Table 1 . Blue plaques were formed at a frequency similar to those previously described (5) . To test whether the appearance of blue plaques in our assay was indeed the result of correct retroviral integration, lambda DNAs from two blue plaques were isolated and the junctions between B a Integration reactions were carried out as previously described (5) . Clone 4, a wild-type MoMLV-producing cell line derived from murine NIH 3T3 cells, was originally made by S. P. Goff (Columbia University, New York). This cell line was obtained from R. Craigie (National Institutes of Health, Bethesda, Md.). Clone 4 and uninfected NIH 3T3 cells were grown in Dulbecco modified Eagle medium with 10% newborn calf serum. The preparation of cytoplasmic extracts from uninfected and MoMLV-infected NIH 3T3 cells was done as previously described (5) . In each reaction, 0.26 pmol of NdeI-linearized (pRP250, pRP255, pRP131, and pRP268) or PvuII-linearized was plated onto Luria-Bertani agar plates. Blue plaques were counted after about 16 h of incubation at 37°C. Total phage titers were determined by plating phage dilutions onto lawns of E. coli NM538 (supF). The columns show the total numbers of plaques on the selective strain (from phage DNAs that have an integrated miniretrovirus) and on the nonselective strain, the ratio between these two (the integration frequency), and the relative integration frequency (relative to the frequency for the mini-MoMLV substrate, expressed as a percentage). Data were pooled from a duplicate set of experiments.
b Extract from uninfected NIH 3T3 cells.
MoMLV (pRP250-Ndel) lambda DNA and integrated mini-MoMLV DNA were sequenced. The sequences are shown in Fig. 2 . In both recombinant phages, the mini-proviral DNAs terminate correctly with the sequence 5'-TG--II--CA-3' and are flanked by a 4-bp directly repeated duplication of the target DNA, which is characteristic of authentic MoMLV integration (18) . Target DNA duplication was checked by comparing the duplicated sequence with the sequence of wild-type lambda DNA (14) .
For mini-HIV-i and mini-HIV-2 substrates, we used plasmids (pRP131 and pRP255) that comprise ends that, after cleavage by NdeI, are identical to the termini of the putative immediate precursors for integration of HIV-1 and HIV-2, except for the presence of the dinucleotide AT at the 5' ends, which is different in wild-type HIV-1 and HIV-2 DNAs. As for the mini-MoMLV substrate, we assume that the crucial aspect is the 3' terminal CA sequence at both ends that ligates to the 5' overhanging target and that minor differences in the 5' overhanging termini of the mini-retroviral DNAs are irrelevant. The results of the integration experiments in which the mini-HIV substrates were used are listed in Table 1 . Both the mini-HIV-1 and the mini-HIV-2 plasmids that contain NdeI cohesive ends were integrated. The frequency of integration of the mini-HIV-1 plasmid is about 20 times lower than the frequency of integration of the mini-MoMLV substrate. The mini-HIV-2 plasmid was integrated at a frequency that is approximately 40 times lower than the integration frequency of the mini-MoMLV plasmid.
To check whether the blue plaques were the product of correct retroviral integration, we isolated lambda DNAs from two blue plaques from each integration reaction and sequenced the junctions between the mini-HIV DNA and lambda DNA. The HIV-1 and HIV-2 substrates were correctly integrated (Fig. 2) VOL. 64, 1990 flanked by 4-bp directly repeated target DNA duplications, which is characteristic for MoMLV integration, and not by 5-bp target DNA duplications, which is characteristic for HIV integration. This suggests that the length of the target DNA duplication is determined by one or more virally encoded proteins (in this study, from MoMLV) and not by the DNA that is integrated (in this study, from HIV). The integration of mini-retroviral DNAs in our assay is dependent on MoMLV, since extracts from uninfected NIH 3T3 cells do not promote integration of the mini-HIV-1 plasmid pRP131 (Table 1) . Although the mini-HIV DNAs are integrated at a lower frequency relative to the frequency of integration of the mini-MoMLV substrate, it is clear from our experiments that not all the nucleotides present at the LTR termini of MoMLV are required for correct integration (Fig. 1B) . It is possible that only the nucleotides that are similar among MoMLV and HIV-1 and HIV-2 (these nucleotides are boxed in Fig. 1B) are necessary for correct integration. It cannot be excluded that for some of the positions the conservation in sequence requirement is partial (e.g., only purines are allowed) and that therefore some of the positions not boxed in Fig. 1B may still be of importance.
To determine whether the cohesive ends that are generated by digestion with NdeI are possibly sufficient substrates for integration, we tested a plasmid that does not contain any viral sequences. We first cloned the supF gene into pUC18, and the resulting plasmid, pRP268, was digested with NdeI and used in the assay. No integration of this substrate was observed ( Table 1 ), indicating that NdeI cohesive ends are not sufficient substrates for integration.
Another mini-retroviral substrate that we tested was a mini-HIV-1 plasmid containing a PvuII restriction site at the boundary between the U3 and U5 terminal sequences (pRP137) (Fig. 1 ). When digested with PvuII, a G nucleotide is present at the 3' ends of this plasmid. Prior to correct integration, this nucleotide will have to be removed by the integration machinery, thereby generating the 3' terminal sequence CA-3'. No integration of substrate pRP137 was detected. This is in agreement with the finding that the MoMLV integration machinery is not able to integrate blunt-ended mini-MoMLV substrates in vitro (5) . A possible explanation might be that the step in vivo preceding the actual integration, the cutting off of the nucleotides beyond the CA-3', is not carried out with sufficient efficiency on exogenous DNA in this cell-free system and might depend on the precise architecture of the endogenous integration complex.
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